Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring

Meropenem demonstrates significant efficacy against severe infections caused by sensitive pathogens, particularly in cases of urinary tract infections. We identified that a C_min of ≥ 5.3 mg/L and a C_max of ≥ 39.4 mg/L are associated with optimal clinical efficacy. Based on these findings, we propose an initial dosing strategy tailored to renal function and the site of infection. Our results underscore the value of early TDM in identifying patients at risk of suboptimal exposure, which provides a crucial foundation for subsequent dose adjustments. Therefore, to optimise meropenem therapy in critically ill patients, it is crucial to implement a TDM-guided strategy that integrates appropriate dosing, prolonged infusion modalities, and early exposure assessment.